261 related articles for article (PubMed ID: 11741249)
41. Discovery of the nonfunctional CYP2D6 31 allele in Spanish, Puerto Rican, and US Hispanic populations.
Gaedigk A; Isidoro-García M; Pearce RE; Sánchez S; García-Solaesa V; Lorenzo-Romo C; Gonzalez-Tejera G; Corey S
Eur J Clin Pharmacol; 2010 Sep; 66(9):859-64. PubMed ID: 20473659
[TBL] [Abstract][Full Text] [Related]
42. CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles.
Leathart JB; London SJ; Steward A; Adams JD; Idle JR; Daly AK
Pharmacogenetics; 1998 Dec; 8(6):529-41. PubMed ID: 9918137
[TBL] [Abstract][Full Text] [Related]
43. Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes.
Kubota T; Yamaura Y; Ohkawa N; Hara H; Chiba K
Br J Clin Pharmacol; 2000 Jul; 50(1):31-4. PubMed ID: 10886115
[TBL] [Abstract][Full Text] [Related]
44. CYP2D6 genotype and phenotype relationship in South Indians.
Naveen AT; Prasanna T; Farzana BL; Rajan S; Adithan C
J Postgrad Med; 2006; 52(4):253-6. PubMed ID: 17102541
[TBL] [Abstract][Full Text] [Related]
45. CYP2D6-related oxidation polymorphism in a Canadian Inuit population.
Jurima-Romet M; Foster BC; Casley WL; Rode A; Vloshinsky P; Huang HS; Geertsen S
Can J Physiol Pharmacol; 1997 Mar; 75(3):165-72. PubMed ID: 9164697
[TBL] [Abstract][Full Text] [Related]
46. The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction.
Rebsamen MC; Desmeules J; Daali Y; Chiappe A; Diemand A; Rey C; Chabert J; Dayer P; Hochstrasser D; Rossier MF
Pharmacogenomics J; 2009 Feb; 9(1):34-41. PubMed ID: 18591960
[TBL] [Abstract][Full Text] [Related]
47. Induction of CYP2D6 in pregnancy.
Wadelius M; Darj E; Frenne G; Rane A
Clin Pharmacol Ther; 1997 Oct; 62(4):400-7. PubMed ID: 9357391
[TBL] [Abstract][Full Text] [Related]
48. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
Streetman DS; Bleakley JF; Kim JS; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577
[TBL] [Abstract][Full Text] [Related]
49. Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use.
Dorado P; Cáceres M; Pozo-Guisado E; Wong ML; Licinio J; Llerena A
Biotechniques; 2005 Oct; 39(10 Suppl):S571-4. PubMed ID: 18957039
[TBL] [Abstract][Full Text] [Related]
50. Evaluation of cytochrome P450 2D6 phenotyping in healthy adult Western Indians.
Gogtay NJ; Mali NB; Iyer K; Kadam PP; Sridharan K; Shrimal D; Thatte UM
Indian J Pharmacol; 2014; 46(3):266-9. PubMed ID: 24987171
[TBL] [Abstract][Full Text] [Related]
51. CYP2D6*36 gene arrangements within the cyp2d6 locus: association of CYP2D6*36 with poor metabolizer status.
Gaedigk A; Bradford LD; Alander SW; Leeder JS
Drug Metab Dispos; 2006 Apr; 34(4):563-9. PubMed ID: 16415111
[TBL] [Abstract][Full Text] [Related]
52. The effect of CYP2D6 polymorphisms on dextromethorphan metabolism in Mexican Americans.
Casner PR
J Clin Pharmacol; 2005 Nov; 45(11):1230-5. PubMed ID: 16239355
[TBL] [Abstract][Full Text] [Related]
53. Comparison of various urine collection intervals for caffeine and dextromethorphan phenotyping in children.
Kennedy MJ; Abdel-Rahman SM; Kashuba AD; Leeder JS
J Clin Pharmacol; 2004 Jul; 44(7):708-14. PubMed ID: 15199075
[TBL] [Abstract][Full Text] [Related]
54. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry.
Chen S; Chou WH; Blouin RA; Mao Z; Humphries LL; Meek QC; Neill JR; Martin WL; Hays LR; Wedlund PJ
Clin Pharmacol Ther; 1996 Nov; 60(5):522-34. PubMed ID: 8941025
[TBL] [Abstract][Full Text] [Related]
55. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
[TBL] [Abstract][Full Text] [Related]
56. CYP2D6 polymorphism in a Mexican American population.
Mendoza R; Wan YJ; Poland RE; Smith M; Zheng Y; Berman N; Lin KM
Clin Pharmacol Ther; 2001 Dec; 70(6):552-60. PubMed ID: 11753272
[TBL] [Abstract][Full Text] [Related]
57. Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation.
Jones DR; Gorski JC; Haehner BD; O'Mara EM; Hall SD
Clin Pharmacol Ther; 1996 Oct; 60(4):374-84. PubMed ID: 8873685
[TBL] [Abstract][Full Text] [Related]
58. CYP2D6 genotype and phenotype in Amerindians of Tepehuano origin and Mestizos of Durango, Mexico.
Sosa-Macías M; Elizondo G; Flores-Pérez C; Flores-Pérez J; Bradley-Alvarez F; Alanis-Bañuelos RE; Lares-Asseff I
J Clin Pharmacol; 2006 May; 46(5):527-36. PubMed ID: 16638736
[TBL] [Abstract][Full Text] [Related]
59. Pharmacogenetic comparison of CYP2D6 predictive and measured phenotypes in a South African cohort.
Dodgen TM; Labuschagne CJ; van Schalkwyk A; Steffens FE; Gaedigk A; Cromarty AD; Alessandrini M; Pepper MS
Pharmacogenomics J; 2016 Nov; 16(6):566-572. PubMed ID: 26503815
[TBL] [Abstract][Full Text] [Related]
60. A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment.
Shiran MR; Chowdry J; Rostami-Hodjegan A; Ellis SW; Lennard MS; Iqbal MZ; Lagundoye O; Seivewright N; Tucker GT
Br J Clin Pharmacol; 2003 Aug; 56(2):220-4. PubMed ID: 12895196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]